Skip to main content
. 2019 Oct 7;9:14364. doi: 10.1038/s41598-019-50892-9

Table 2.

Laboratory findings and follow-up results of GCA patients according to TB.

GCA with TB GCA without TB P value
Mean ± SD (range) n (%) Total n Mean ± SD (range) n (%) Total n
Laboratory findings
ESR (mm/h) 94.50 ± 28.21 (44−140) 20 90.01 ± 27.74 (21−140) 71 0.526
CRP (mg/L) 76.71 ± 59.67 (2.47−197) 20 80.68 ± 63.45 (1.8−275.66) 71 0.803
ALB (g/L) 33.20 ± 5.65 (24−47) 20 32.38 ± 4.30 (22−42) 69 0.486
WBC ( × 109/L) * 6.92 ± 2.39 (1.47−10.91) 20 9.80 ± 4.42 (2.36−26.60) 69 0.006
Leukopenia 3 (15) 20 3 (4.3) 69 0.148
LYM ( × 109/L) 1.65 ± 0.67 (0.62−2.94) 20 1.63 ± 0.78 (0.40−4.20) 69 0.914
HGB (g/L) 100.30 ± 17.14 (63−132) 20 108.84 ± 19.86 (63−146) 69 0.085
PLT ( × 109/L) 400.20 ± 151.07 (130−653) 20 373.75 ± 152.83 (99−725) 69 0.496
Fbg (g/L) 6.25 ± 2.69 (2.90−10.00) 20 5.30 ± 2.12 (2.00−10.49) 57 0.100
ANA positive 6 (30) 20 12 (17.6) 68 0.229
ANCA positive 1 (5) 20 12 (18.8) 64 0.138
APS positive* 5 (55.6) 9 5 (14.7) 34 0.010
4 LA + 1 ACL+ 4 ACL  + 1 β 2GP1 + 1 positive for 3 antibodies
Elevated RF 2 (15.4) 13 17 (33.3) 51 0.206
Elevated IgG* 7 (50) 14 14 (23.3) 60 0.046
Follow-up results
Non-relapsing 11 (64.7) 17 26 (43.3) 60 0.119
Relapsing 2 (11.8) 17 24 (40) 60 0.027
Comorbid with tumors 1 (5.9) 17 1 (1.7) 60 0.335
Death 3 (17.6) 17 9 (15) 60 0.791

ALB, Albumin; ACL, anti-cardiolipin antibody; ANA, anti-nuclear antibody; ANCA, anti-neutrophil cytoplasmic antibody; APS, anti-phospholipid antibody; β 2GP1, β2glycoprotein1; CRP, C-reactive protein; ESR, erythrocyte sedition rate; Fbg, fibrinogen; GCA, giant cell arteritis HGB, hemoglobin; Ig G, immunoglobin G; LA, lupus anticoagulant; LYM, lymphocyte; PLT, platelet; RF, rheumatic factor; SD, standard deviation; TB, tuberculosis; WBC, white blood cell. *Significantly different.